Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020
05 nov. 2020 16h35 HE
|
Cellectis Inc.
Sponsored program at ASH 2020 – Oral presentation of initial data for BALLI-01 clinical trial evaluating UCART22 product candidate in adult patients with R/R B-cell Acute Lymphoblastic Leukemia...
Cellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 at 8:00AM EST
21 oct. 2020 16h30 HE
|
Cellectis Inc.
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited...
Cellectis to Participate in Upcoming Investor Conferences
02 sept. 2020 16h56 HE
|
Cellectis Inc.
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited...